Immunotherapy may let some GI cancer patients skip the knife
NCT ID NCT07656740
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at whether immunotherapy can shrink certain gastrointestinal cancers (like colorectal or stomach cancer) enough that some patients may not need major surgery. People whose tumors have specific genetic features (MSI-H/dMMR or POLE mutation) and who respond well to immunotherapy may be able to simply watch and wait or have a minor procedure instead of a radical operation. The goal is to see if this approach can preserve organ function and avoid permanent colostomy while keeping the cancer under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
immunotherapy (neoadjuvant)
What this could lead to
If successful, this could allow some patients with certain GI cancers to avoid major surgery and preserve organ function.
What could go wrong
This is an early-stage study with only 50 participants, so results may not apply broadly. There is a risk that the cancer may return without surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Peking University Cancer Hospital
Beijing, Haidian District, 100142, China
Contact Phone: •••-•••-•••• Email: •••••@•••••